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Purpose:  Patients  with  normal  stress  myocardial  perfusion  imaging  (MPI)  results  generally  have  an  excel-
lent prognosis  with  <1%  cardiovascular  events/year.  Chronic  kidney  disease  (CKD)  is an established  risk
factor  for  cardiovascular  events.  However,  the  estimated  glomerular  ﬁltration  rate  (eGFR)  varies  consid-
erably among  patients  with  CKD.  We  evaluated  the  prognostic  value  of  eGFR  for patients  with  CKD  who
did  not  undergo  hemodialysis  and  had  no  evidence  of coronary  artery  disease  (CAD).
Methods  and subjects:  Patients  with  CKD  (n =  108;  58 males;  mean  age:  74  years)  with  no  CAD [no previous
CAD  and  normal  stress  MPI  results;  summed  stress  score  (SSS)  <4] and  with  no history  of  hemodialysis
were  followed-up  (mean  duration:  24  months).  CKD  was  deﬁned  by eGFR  of  <60  ml/min/1.73  m2 and/or
persistent  proteinuria.  Cardiovascular  events  included  cardiac  death,  non-fatal  myocardial  infarction,
and  unstable  angina.
Results: Cardiovascular  events  were  observed  in 8  patients  with  CKD  (7%).  The  following  were  deter-
mined  as  signiﬁcant  predictors  of these  events:  age (hazard  ratio  =  1.14;  p = 0.019),  hemoglobin  levels
(hazard  ratio =  0.69; p =  0.021),  eGFR  (hazard  ratio  =  0.94;  p =  0.008),  SSS  (hazard  ratio  = 2.31; p =  0.012),
and  summed  difference  score  (hazard ratio = 2.33;  p = 0.014).
Conclusions:  Patients  with  CKD  and  with  no previous  CAD  and  normal  stress  MPI  results  (SSS  <  4) may  not
exhibit  an  excellent  cardiovascular  prognosis.  Further,  a lower  eGFR  and  stress  MPI  results  may  be the
predictors  of cardiovascular  events.  Thus,  patients  with  a lower  eGFR  and/or  normal  stress  MPI results
(SSS  <  4) may  require  continuous  follow-up.
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Stress myocardial perfusion imaging (MPI) is useful for pre-
icting cardiovascular events such as mortality because of cardiac
ailure and acute coronary syndrome [1–3]. In general, normal
tress MPI  results are associated with an excellent cardiovascu-
ar prognosis with <1% cardiovascular events/year [4]. In addition,
ssociations between chronic kidney disease (CKD) and adverse
ardiovascular prognosis were established in large community-
ased studies [5–10]; however, few previous reports indicated that
ven for patients with normal stress MPI  results an excellent prog-
osis for cardiovascular events could not be guaranteed [11–13].
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The estimated glomerular ﬁltration rate (eGFR) varies consider-
ably among the patients with CKD. In this study, we assessed the
prognostic value of eGFR for patients with CKD who  did not undergo
hemodialysis and had no evidence of coronary artery disease (CAD),
as assessed by clinical history and stress MPI  results.
Materials and methods
Patients and study protocol
This was a retrospective prognostic study for patients who
underwent stress MPI. A total of 1002 consecutive patients
with suspected or prior CAD underwent thallium-201 stress MPI
between 2008 and 2010. The following patients were excluded
from this study: 144 patients for whom no prognostic data could
be obtained after stress MPI; 15 with a summed difference score
(SDS) of >2 on stress MPI  and in whom revascularization was
achieved within 2 months of percutaneous coronary intervention
vier Ltd. All rights reserved.
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performed to manage signiﬁcant ischemia) [14]; 8 with severe
alvular disease requiring surgery; 3 with severe aortic disease
equiring surgery; 297 without CKD; 67 receiving dialysis; 348 with
 history of CAD; and 12 with abnormal stress MPI  results [summed
tress scores (SSS) ≥4].
Finally, 108 CKD patients were followed up (Fig. 1). All the
atients provided informed consent to participate in this study. Our
tudy protocol was approved by the Committee on Human Investi-
ation of the Toho University Ohashi Medical Center (approval No.
2-62). This study was conducted in accordance with the ethical
tandards of the 1964 Declaration of Helsinki (as revised in Tokyo,
004) and subsequent revisions.
The following patient data had been recorded during pre-
ious stress MPI: age, gender, use of medication, and other
oronary risk factors. The following were considered as possi-
le risk factors for this study: cigarette smoking and history of
ypertension (systolic blood pressure >140 mm Hg, diastolic blood
ressure >90 mm Hg, and/or anti-hypertensive therapy); diabetes
fasting blood glucose >126 mg/dl, glycosylated hemoglobin >6.5%
ased on the National Glycohemoglobin Standardization Program
eﬁnition, currently undergoing treatment with insulin or oral
nti-diabetic drugs), hyperlipidemia [hypercholesterolemia (total
holesterol >220 mg/dl), hypertriglyceridemia (serum triglycerides
150 mg/dl), and/or currently undergoing lipid lowering therapy];
nd history of CAD incidence among ﬁrst-degree relatives at <60
ears of age.
Exercise or pharmacological stress tests were performed. All
he exercise stress tests were performed using a treadmill. None
f the patients underwent ergometer exercise stress testing. The
readmill exercise test (Bruce protocol) was considered adequate
f patients achieved >85% of their maximum predicted heart rate
nd/or developed chest pain. Further, patients with limited exer-
ise capacity (who failed to achieve at least 85% of their predicted
eart rate during the treadmill test) underwent a pharmacological
tress test comprising intravenous adenosine infusion. Adenosine
nfusion and thallium-201 injection were administered in sep-
rate arms. An automated infusion pump was used to deliver
he intravenous adenosine infusion (0.120 mg/kg/min) over 6 min.
hallium-201 (111 MBq; FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan)
as injected into a peripheral vein approximately 1 min  before
essation of the treadmill stress test or 3 min  after initiating the
denosine infusion.
yocardial perfusion single-photon emission computed
omographyAll myocardial perfusion single-photon emission tomographic
ata were acquired using a 3-headed gamma  camera (MS-3;
iemens, Chicago, IL, USA) equipped with a low-energy cardiofo-
al collimator and a computer interface (ICON; Siemens). Stress
ig. 1. Flow diagram for the study population. MPI, myocardial perfusion imaging;
AD, coronary artery disease; CKD, chronic kidney disease.diology 63 (2014) 154–158 155
single-photon emission computed tomography (SPECT) was  per-
formed 10 min  after stress testing, and resting SPECT was
performed 4 h after stress imaging. Ninety projections were
acquired for 20 s each in 4/360◦ intervals and stored in 64 × 64
matrices. A 15% symmetrical energy window, centered on the 70-
keV peak, was  used. Tomographic reconstruction was  performed
by the standard ﬁltered back-projection technique using a Butter-
worth ﬁlter with a cutoff frequency of 0.5 cycles/pixel and an order
of 5. No corrections were made for attenuation or scatter.
SPECT images were reoriented along the short, horizontal, and
vertical long axes for analysis. SPECT data analysis was  performed
on the basis of agreement among 2 or more experienced radiolo-
gists, who  were blinded to patient identity and clinical information.
Defects were classiﬁed as reversible (including partially reversible)
or ﬁxed (irreversible). SPECT images were assessed to determine
the presence, location, and severity of any perfusion defects. The
left ventricle was divided into 17 segments, and each segment
was assigned a score using a 5-point scoring system (0 = normal;
1 = mildly reduced; 2 = moderately reduced; 3 = severely reduced;
and 4 = uptake absent). The sum of SSS, scores at rest (summed rest
score; SRS), and the difference between stress and resting scores
(SDS) were calculated. The score for each myocardial segment on
the images was calculated, and a stress score for each segment
was determined. As demonstrated in previous studies, based on
an excellent cardiovascular prognosis, patients with SSS of <4 were
considered to be normal [3,15,16]. Quantitative gated SPECT (QGS)
was not usually performed at our institution. Therefore, only 18
patients were assessed by QGS.
CKD classiﬁcations
eGFR was  calculated using the 4-variable Modiﬁed Diet
in the Renal Disease equation [17]: eGFR = 175 × serum creat-
inine (mg/dl) − 1.154 × age − 0.203 × 0.741 (Japanese) × 0.742 (if
female).
eGFR was  determined at a mean of 30 ± 23 days from
the time of conduction of MPI. CKD was  deﬁned accord-
ing to National Kidney Foundation criteria [18] as eGFR of
<60 ml/min/1.73 m2 and/or persistent proteinuria for >3 months.
CKD was categorized into the following stages depending on
the basis of eGFR: Stage I > 90 ml/min/1.73 m2 (n = 7); Stage II
60–90 ml/min/1.73 m2 (n = 27); Stage III 30–60 ml/min/1.73 m2
(n = 51); Stage IV 15–30 ml/min/1.73 m2 (n = 16); and Stage
V < 15 ml/min/1.73 m2 (n = 7). None of the patients in this study suf-
fered acute renal failure (deﬁned by >0.5 mg/dl increase in serum
creatinine levels in <2 weeks, or an increase of >20% over baseline
if serum creatinine levels were >2.5 mg/dl).
Echocardiography and ankle brachial index
The left ventricular ejection fraction (LVEF) was measured by M-
mode echocardiography within 1 month of MPI. Peripheral arterial
disease (PAD) was  deﬁned on the basis of previous medical his-
tory and/or an ankle brachial index of <0.9 [19,20] and/or previous
angioplasty for peripheral arteries.
Endpoints and follow-up
Follow-up commenced after assessing cardiac function and
stress MPI. Endpoints were cardiac death, nonfatal myocardial
infarction (MI), and Braunwald class III unstable angina requiring
hospitalization. Cardiac deaths included sudden cardiac death, fatal
MI,  death due to heart failure, or death due to arrhythmia. Sudden
cardiac death was deﬁned as witnessed cardiac arrest, death within
1 h of onset of acute symptoms, or unexpected death for those who
had been considered well for the previous 24 h. Braunwald class III
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nstable angina was deﬁned as acute angina at rest within 48 h of
nset. All of these endpoints were deﬁned as cardiovascular events.
atients were followed up regularly for a mean of 25 ± 14 months
range: 1–49 months).
tatistical analysis
Results are presented as means ± standard deviations. Chi-
quare tests were used to compare patients with and without
ardiovascular events with regard to gender, underlying diseases,
nd medical treatments. Student’s t-tests were used to compare
he two groups with regard to age, BMI, echocardiography param-
ters, and stress MPI  results. Cox regression hazard analysis was
sed to assess the possible risk factors. Kaplan–Meier event-free
urves were generated, and the risks of cardiovascular events were
ompared between patient groups using log rank tests. Statisti-
al analyses were performed using the SPSS software (SPSS Inc.,
hicago, IL, USA). A p-value of <0.05 was considered signiﬁcant.
esults
atient characteristics
Table 1 summarizes our patients’ baseline characteristics. There
ere no signiﬁcant differences with regard to age, gender, hyper-
ension, hyperlipidemia, history of smoking, family history of
AD, cerebral artery disease, and PAD between patients with
nd without cardiovascular events. With regard to laboratory test
esults, serum albumin levels and eGFR were signiﬁcantly lower in
atients with cardiovascular events than those without. However,
able 1
atient characteristics.
Overall (N = 108) Ev
Age 73 ± 12 81
Male  68 (63%) 5 
Hypertension 92 (85%) 7 
Diabetes 40 (37%) 5 
Hyperlipidemia 60 (56%) 4 
History of smoking 56 (52%) 3 
Family history of CAD 13 (12%) 0 
Cerebral vascular disease 17 (16%) 2 
PAD  20 (19%) 3 
Laboratory data
Hemoglobin 12.4 ± 2.0 11
Albumin 4.0 ± 0.5 3.
eGFR  51 ± 24 32
HbA1c 5.9 ± 1.1 6.
LDL  cholesterol 104 ± 34 10
HDL  cholesterol 56 ± 16 58
Echocardiography
LVDd 46 ± 7.4 47
LVDs  30 ± 7.7 35
LVEF  65 ± 13 57
Adenosine stress test 83 (77%) 8 
Myocardial perfusion images
SSS 0.5 ± 0.9 1.
SRS  0.2 ± 0.5 0.
SDS  0.4 ± 0.8 0.
Follow-up period (months) 25 ± 14 19
Medication
Aspirin 38 (35%) 2 
ACE-I/ARB 81 (75%) 7 
Beta-blocker 32 (30%) 1 
Nitrates 8 (7%) 0 
Diuretics 37 (34%) 5 
Insulin 21 (19%) 3 
Statins 44 (41%) 4 
AD, coronary artery disease; PAD, peripheral artery disease; eGFR, estimated glomerular
DL,  high density lipoprotein; LVDd, left ventricular diastolic diameter; LVDs, left ventric
core;  SRS, summed rest score; SDS, summed difference score; ACE-I, angiotensin-converdiology 63 (2014) 154–158
on the basis of echocardiography results, no signiﬁcant differences
were observed between patients with and without cardiovascular
events. Furthermore, no signiﬁcant difference was observed with
regard to the rate of undergoing adenosine stress testing between
the patients with and without cardiovascular events. In addition, no
signiﬁcant difference was  observed with regard to the stress MPI
scores (SSS, SRS, and SDS) between patients with and without car-
diovascular events. However, SSS and SDS tended to be higher for
patients with cardiovascular events than those without (p = 0.06 for
SSS, and p = 0.07 for SDS). With regard to medication use, there were
no signiﬁcant differences between in patients with and without
cardiovascular events.
Outcomes
During a mean follow-up period of 25 months, cardiovascular
events were observed for 8 patients: cardiac death (n = 5); nonfa-
tal MI  (n = 2); and Braunwald type III unstable angina (n = 1). With
regard to CKD stages, cardiovascular events were observed for none
of the 7 patients (0%) with Stage I, 1 of the 27 (4%) with Stage II, 2
of the 51 (4%) with Stage III, 3 of the 16 (19%) with Stage IV, and 2
of the 7 (29%) with Stage V.
We used univariate Cox regression hazard analysis to assess
the possible risk factors for cardiovascular events (Table 2). Age,
hemoglobin levels, eGFR, and SSS and SDS of stress MPI  scores were
the signiﬁcant predictors of cardiovascular events. As previously
noted, the minimum number of variables that should be entered
into a multivariable model is a function of the number of events
that occurred during the study. In general, 1 variable per 10 events
is strongly recommended [21]. Thus, because of the small number
ents + (N = 8) Events − (N = 100) p-value
 ± 5.0 73 ± 12 n.s.
(63%) 63 (63%) n.s.
(88%) 85 (85%) n.s.
(55%) 35 (35%) n.s.
(50%) 56 (56%) n.s.
(38%) 53 (53%) n.s.
(0%) 13 (13%) n.s.
(25%) 15 (15%) n.s.
(38%) 17 (17%) n.s.
.2 ± 1.9 12.6 ± 2.0 n.s.
6 ± 0.4 4.0 ± 0.5 0.004
 ± 19 52 ± 24 0.024
2 ± 1.6 5.9 ± 1.0 n.s.
5 ± 44 104 ± 34 n.s.
 ± 20 56 ± 15 n.s.
 ± 12 46 ± 7.0 n.s.
 ± 14 30 ± 7.1 n.s.
 ± 16 65 ± 12 n.s.
(100%) 75 (75%) n.s.
1 ± 1.2 0.5 ± 0.9 n.s.
3 ± 0.7 0.2 ± 0.5 n.s.
9 ± 1.2 0.3 ± 0.8 n.s.
 ± 11 26 ± 13 n.s.
(25%) 36 (36%) n.s.
(88%) 74 (74%) n.s.
(13%) 31 (31%) n.s.
(0%) 8 (8%) n.s.
(63%) 32 (32%) n.s.
(38%) 18 (18%) n.s.
(50%) 40 (40%) n.s.
 ﬁltration rate; HbA1c, glycosylated hemoglobin A1c; LDL, low density lipoprotein;
ular systolic diameter; LVEF, left ventricular ejection fraction; SSS, summed stress
ting enzyme inhibitor; ARB, angiotensin II receptor blocker.
T. Furuhashi et al. / Journal of Car
Table  2
Univariate Cox regression analysis.
Hazard ratio 95% CI p-value
Male 0.86 0.21–3.62 n.s.
Age  1.14 1.02–1.26 0.019
Cerebral vascular disease 2.02 0.41–10.0 n.s.
Peripheral artery disease 3.61 0.84–15.4 n.s.
Hypertension 1.49 0.18–12.2 n.s.
Diabetes 4.03 0.96–16.9 n.s.
Smoking history 0.47 0.11–1.98 n.s.
Laboratory data
Hemoglobin 0.69 0.51–0.95 0.021
eGFR 0.94 0.91–0.99 0.008
Echocardiography
LVEF 0.95 0.90–1.00 n.s.
Myocardial perfusion images
SSS 2.31 1.21–4.42 0.011
SRS  1.46 0.52–4.07 n.s.
SDS  2.33 1.18–4.57 0.014
eGFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction;
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f cardiovascular events, multivariate Cox regression analysis could
ot be used to assess the relative strength of these risks among the
ariables that demonstrated relatively strong signiﬁcance.
Fig. 2 displays the Kaplan–Meier survival curves for free-
om from cardiovascular events for patients with eGFR of
45 ml/min/1.73 m2 and those with eGFR of <45 ml/min/1.73 m2
fter the application of a threshold value used in a previous
tudy [6]. As presented in Fig. 2, the prognoses of cardiovas-
ular events were signiﬁcantly different between patients with
GFR ≥45 ml/min/1.73 m2 and those with eGFR <45 ml/min/1.73
2 (p = 0.014 by log rank test).
iscussion
Stress MPI  is an established technique for CAD diagnosis and
rognosis [1–3]. In general, normal ﬁndings on stress MPI  are
ssociated with a low risk of cardiac death and acute myocar-
ial infarction with an annual event rate of <1% [2,3,22–26]. Even
or patients with normal stress MPI  results (SSS < 4), the cardiac
ig. 2. Kaplan–Meier survival curves for freedom from cardiovascular events for
atients with estimated glomerular ﬁltration rate (eGFR) of ≥45 ml/min/1.73 m2
nd those with eGFR of <45 ml/min/1.73 m2. Although the number of cardiovas-
ular events was  small, the prognosis for cardiovascular events was  signiﬁcantly
etter for patients with eGFR of ≥45 ml/min/1.73 m2 than for those with eGFR of
45  ml/min/1.73 m2.diology 63 (2014) 154–158 157
mortality rate is signiﬁcantly higher for patients with CKD com-
pared with that in those without CKD (2.7% vs. 0.8%; p < 0.0001)
[11]. With regard to patients with no evidence of CAD on stress
MPI, CKD may be an independent and signiﬁcant risk factor for
cardiovascular events; normal stress MPI  results cannot guarantee
an excellent prognosis for patients with CKD [12,13,27]. Therefore,
our study results suggest that patients with CKD, particularly those
with a lower eGFR, should receive aggressive medical management
to prevent cardiovascular events. As indicated in Fig. 2, the patients
with eGFR of ≥ 45 ml/min/1.73 m2 exhibited relatively good prog-
nosis with regard to absence of cardiovascular events: only 2 events
were observed at 7 months and at 38 months after stress MPI.
In contrast, patients with eGFR of <45 ml/min/1.73 m2 exhibited
poor prognosis: 6 events were observed at 6, 14, 15, 20, 25, and
26 months after stress MPI. Moreover, with regard to patients
with lower eGFR, cardiovascular events were observed more fre-
quently, particularly at >1 year after stress MPI. Even for patients
with normal stress MPI  results (deﬁned as SSS < 4) and no history
of CAD, a lower eGFR may  be associated with poor cardiovascu-
lar prognosis. This suggests that patients with a lower eGFR may
require intensive therapy such as aspirin and/or nitrates as well as
careful and persistent follow-up. Additional studies are needed to
investigate the signiﬁcance of intensive therapy for these patients,
and we consider that frequent stress MPI follow-up (e.g. every
1–2 years) is useful for preventing cardiovascular events. In this
study, a minimum defect detected on stress MPI, which had pre-
viously been considered as being within normal limits, may  have
been a predictor of cardiovascular events for pre-dialysis patients
with CKD. It is possible that for these patients, even a minimum
range of myocardial ischemia plus infarction (SSS) and myocar-
dial ischemia (SDS), which are generally considered as normal,
have predictive value for cardiovascular events. In addition, we
assessed the relationship between eGFR and stress MPI  results.
With regard to patients with eGFR of ≥45 ml/min/1.73 m2 and those
with eGFR of <45 ml/min/1.73 m2, both SSS (0.5 ± 0.9 vs. 0.6 ± 1.0,
p = n.s.) and SDS (0.3 ± 0.7 vs. 0.5 ± 0.9, p = n.s.) revealed no signif-
icant difference: therefore, we observed no relationship between
these variables.
Compared with the general population, patients with CKD
also have additional cardiovascular risk factors, including anemia
and abnormal calcium/phosphorus metabolism, which promote
increased vascular calciﬁcation and decreased oxygen-carrying
capacity [28]. Moreover, factors related to water volume control
and electrolytes such as potassium/sodium imbalance may  also
increase their risk for cardiovascular events.
In this study, among patients in different CKD stage categories,
eGFR was not a signiﬁcant predictor of cardiovascular events owing
to the small numbers of patients and events with each stage. There-
fore, we will need to assess the cardiovascular prognosis with a
larger number of patients with CKD.
QGS was performed only for 18 patients, and 2 of them had
cardiovascular events. In addition, compared with technetium,
thallium was  not suitable for QGS. We  could not assess the pre-
dictive values of the cardiac function parameters such as left
ventricular end-diastolic volume, left ventricular end-systolic vol-
ume, left ventricular ejection fraction, or the peak ﬁlling rate
measured by QGS.
Conclusion
Normal stress MPI  results, deﬁned as SSS < 4, were not associated
with an excellent cardiovascular prognosis for pre-dialysis patients
with CKD and without a history of prior CAD. A lower eGFR and a
minimal stress MPI  abnormality may  possibly predict cardiovascu-
lar events in these patients.
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